Literature DB >> 26649486

IFN-γ-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells.

Joris Ramstein1, Caroline E Broos2, Laura J Simpson3,4, K Mark Ansel3,4, Sara A Sun1, Melissa E Ho1, Prescott G Woodruff1, Nirav R Bhakta1, Laura Christian3,4, Christine P Nguyen1, Bobby J Antalek1, Bryan S Benn1, Rudi W Hendriks2, Bernt van den Blink2, Mirjam Kool2, Laura L Koth1.   

Abstract

RATIONALE: Pulmonary sarcoidosis is classically defined by T-helper (Th) cell type 1 inflammation (e.g., IFN-γ production by CD4(+) effector T cells). Recently, IL-17A-secreting cells have been found in lung lavage, invoking Th17 immunity in sarcoidosis. Studies also identified IL-17A-secreting cells that expressed IFN-γ, but their abundance as a percentage of total CD4(+) cells was either low or undetermined.
OBJECTIVES: Based on evidence that Th17 cells can be polarized to Th17.1 cells to produce only IFN-γ, our goal was to determine whether Th17.1 cells are a prominent source of IFN-γ in sarcoidosis.
METHODS: We developed a single-cell approach to define and isolate major Th-cell subsets using combinations of chemokine receptors and fluorescence-activated cell sorting. We subsequently confirmed the accuracy of subset enrichment by measuring cytokine production.
MEASUREMENTS AND MAIN RESULTS: Discrimination between Th17 and Th17.1 cells revealed very high percentages of Th17.1 cells in lung lavage in sarcoidosis compared with controls in two separate cohorts. No differences in Th17 or Th1 lavage cells were found compared with controls. Lung lavage Th17.1-cell percentages were also higher than Th1-cell percentages, and approximately 60% of Th17.1-enriched cells produced only IFN-γ.
CONCLUSIONS: Combined use of surface markers and functional assays to study CD4(+) T cells in sarcoidosis revealed a marked expansion of Th17.1 cells that only produce IFN-γ. These results suggest that Th17.1 cells could be misclassified as Th1 cells and may be the predominant producer of IFN-γ in pulmonary sarcoidosis, challenging the Th1 paradigm of pathogenesis.

Entities:  

Keywords:  chemokine receptor; inflammation; lymphocyte

Mesh:

Substances:

Year:  2016        PMID: 26649486      PMCID: PMC4910899          DOI: 10.1164/rccm.201507-1499OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  46 in total

1.  Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis.

Authors:  M Möllers; S P Aries; D Drömann; B Mascher; J Braun; K Dalhoff
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

Review 2.  T-lymphocytes and cytokines in sarcoidosis.

Authors:  Carlo Agostini; Alessia Meneghin; Gianpietro Semenzato
Journal:  Curr Opin Pulm Med       Date:  2002-09       Impact factor: 3.155

3.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

4.  Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features.

Authors:  Cecilia Lindestam Arlehamn; Gregory Seumois; Anna Gerasimova; Charlie Huang; Zheng Fu; Xiaojing Yue; Alessandro Sette; Pandurangan Vijayanand; Bjoern Peters
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

5.  Restricted V alpha 2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3.

Authors:  J Grunewald; C H Janson; A Eklund; M Ohrn; O Olerup; U Persson; H Wigzell
Journal:  Eur J Immunol       Date:  1992-01       Impact factor: 5.532

Review 6.  Human Th17 subsets.

Authors:  Federica Sallusto; Christina E Zielinski; Antonio Lanzavecchia
Journal:  Eur J Immunol       Date:  2012-09       Impact factor: 5.532

7.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity.

Authors:  G W Hunninghake; R G Crystal
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

8.  Interleukin-23 drives intestinal inflammation through direct activity on T cells.

Authors:  Philip P Ahern; Chris Schiering; Sofia Buonocore; Mandy J McGeachy; Dan J Cua; Kevin J Maloy; Fiona Powrie
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

9.  Imbalance between Th17 and regulatory T-Cells in sarcoidosis.

Authors:  Hui Huang; Zhiwei Lu; Chunguo Jiang; Jia Liu; Yanxun Wang; Zuojun Xu
Journal:  Int J Mol Sci       Date:  2013-10-30       Impact factor: 5.923

10.  Phenotypic and functional features of human Th17 cells.

Authors:  Francesco Annunziato; Lorenzo Cosmi; Veronica Santarlasci; Laura Maggi; Francesco Liotta; Benedetta Mazzinghi; Eliana Parente; Lucia Filì; Simona Ferri; Francesca Frosali; Francesco Giudici; Paola Romagnani; Paola Parronchi; Francesco Tonelli; Enrico Maggi; Sergio Romagnani
Journal:  J Exp Med       Date:  2007-07-16       Impact factor: 14.307

View more
  67 in total

1.  Clinical and Biological Insights from the University of California San Francisco Prospective and Longitudinal Cohort.

Authors:  Bryan S Benn; Zoe Lehman; Sharon A Kidd; Melissa Ho; Sara Sun; Joris Ramstein; Nicholas K Arger; Christine P Nguyen; Robert Su; Antonio Gomez; Jeffrey M Gelfand; Laura L Koth
Journal:  Lung       Date:  2017-07-13       Impact factor: 2.584

2.  Update in Interstitial Lung Disease 2016.

Authors:  Athol U Wells; Toby M Maher
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

3.  Sarcoidosis and T-Helper Cells. Th1, Th17, or Th17.1?

Authors:  Steve N Georas; Timothy J Chapman; Elliott D Crouser
Journal:  Am J Respir Crit Care Med       Date:  2016-06-01       Impact factor: 21.405

4.  Breaking Steroid Resistance: Effect of Vitamin D on IL-23.

Authors:  Cameron H Flayer; Erik D Larson; Angela Haczku
Journal:  Am J Respir Cell Mol Biol       Date:  2017-09       Impact factor: 6.914

Review 5.  Potential immunotherapies for sarcoidosis.

Authors:  Van Le; Elliott D Crouser
Journal:  Expert Opin Biol Ther       Date:  2018-01-17       Impact factor: 4.388

6.  Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma.

Authors:  Juliana Durack; Laura S Christian; Snehal Nariya; Jeanmarie Gonzalez; Nirav R Bhakta; K Mark Ansel; Avraham Beigelman; Mario Castro; Anne-Marie Dyer; Elliot Israel; Monica Kraft; Richard J Martin; David T Mauger; Stephen P Peters; Sharon R Rosenberg; Christine A Sorkness; Michael E Wechsler; Sally E Wenzel; Steven R White; Susan V Lynch; Homer A Boushey; Yvonne J Huang
Journal:  J Allergy Clin Immunol       Date:  2020-04-13       Impact factor: 10.793

7.  Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.

Authors:  Hajir Ibraheim; Esperanza Perucha; Nick Powell
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 8.  Sarcoid-like reaction in cases treated by checkpoint inhibitors.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2021-02-18       Impact factor: 3.064

9.  DNA Methylation Changes in Lung Immune Cells Are Associated with Granulomatous Lung Disease.

Authors:  Ivana V Yang; Iain Konigsberg; Kristyn MacPhail; Li Li; Elizabeth J Davidson; Peggy M Mroz; Nabeel Hamzeh; May Gillespie; Lori J Silveira; Tasha E Fingerlin; Lisa A Maier
Journal:  Am J Respir Cell Mol Biol       Date:  2019-01       Impact factor: 6.914

Review 10.  Genetic, Immunologic, and Environmental Basis of Sarcoidosis.

Authors:  David R Moller; Ben A Rybicki; Nabeel Y Hamzeh; Courtney G Montgomery; Edward S Chen; Wonder Drake; Andrew P Fontenot
Journal:  Ann Am Thorac Soc       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.